Stoke Therapeutics

Stoke Therapeutics

Edit info

  • Founded: 2014
  • Location: Bedford, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin1/Clin2
  • Therapy area: Dravet syndrome (ODD)
  • Drug types: GEN, NEU, OPH, PED
  • Lead product: STK-001
  • Funding: $97.5M stock Nov 2020; $142M IPO Jun 2019; $90M B Oct 2018; $40M A Jan 2018


stoketherapeutics.com

linkedin.com

job board


Business:

Antisense Oligonucleotide Medicines

Drug notes:

STK-002 Clin1 autosomal dominant optic atrophy; undisclosed RD SYNGAP1 syndrome; undisclosed RD Rett syndrome; undisclosed RD CNS condition

About:

Stoke Therapeutics is using new insights in RNA biology to address the underlying cause of severe diseases. Many diseases arise when one copy of a gene functions normally and the other is mutated, called haploinsufficiency. Using their Targeted Augmentation of Nuclear Gene Output (TANGO) platform, Stoke is identifying ways to restore missing proteins by increasing protein output from healthy genes, thereby compensating for the non-functioning copy of the gene. The platform involves the design of antisense oligonucleotides (ASOs) that bind to pre-mRNA and help the target genes produce more protein. Stoke is currently applying their technology to patients with Dravet syndrome, a severe and progressive genetic epilepsy.

Stoke Therapeutics
Vice President, Head of Financial Planning & Analy...
Cambridge, MA|10 days ago
Apply
Stoke Therapeutics
Manager, Information Security
Bedford, MA|37 days ago
Stoke Therapeutics
**. *********, *********** *** *** *************
*********, **|63 days ago


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com